Loading page
Loading page
Loading substance route
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Assumed to be non-addictive with low abuse potential based on similarity to LSD. Animal studies with LSD show no successful self-administration, indicating lack of reinforcing pharmacology necessary to initiate or maintain dependence.
No physical dependence expected. Virtually no withdrawal syndrome is reported when chronic LSD use is stopped, and 1V-LSD is assumed to share this property.
No known toxic dose. Based on similarity to LSD, 1V-LSD is assumed to be physiologically well-tolerated with extremely low toxicity relative to dose. Relatively few physical side effects have been reported following acute exposure.
May act as a trigger for psychotic episodes in individuals with underlying mental disorders or family history of mental illness. Higher doses increase the risk of adverse psychological reactions including delusions. Those with personal or family history of mental illness are advised not to use this substance outside supervised medical settings.
Seizures are rare but have been reported with LSD, from which 1V-LSD's risk is extrapolated. Primarily a concern in genetically predisposed individuals, particularly when accompanied by physically taxing conditions such as dehydration, fatigue, undernourishment, or overheating.
1V-LSD emerged on the online research chemical market in June or July of 2021. Its appearance coincided with the announcement of new German scheduling controls targeting 1cP-LSD under the Neue-psychoaktive-Stoffe-Gesetz (NpSG), suggesting the compound was developed and released specifically as a…
Not scheduled under UN Convention on Psychotropic Substances
Not technically illegal as a specific substance, but may fall under the Neue-Psychoaktive-Substanzen-Gesetz (NPSG) as an analogue of LSD, making it illegal to supply for human consumption.
Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act). An initial amendment in September 2022 failed to take effect due to a punctuation error in the legislation. The law was corrected in March 2023, effectively banning 1V-LSD. Production and import with intent to market, administration to another person, and trading are punishable offenses. Possession is illegal but not penalized.
Although not officially scheduled as a named substance, it is controlled as an LSD structural analogue pursuant to an amendment implemented on June 1, 2015.
Has been under investigation by Swedish authorities since March 2, 2022 for potential scheduling. May become a controlled substance pending review outcome.
Classified as a controlled drug substance. Possession, production, supply, and importation are all prohibited under Turkish drug laws.
Not specifically scheduled under the Controlled Substances Act. However, since 1V-LSD functions as a prodrug for LSD, its possession and sale may be prosecutable under the Federal Analogue Act when sold or possessed with intent for human consumption.
Not a controlled substance under Canadian drug legislation. No specific scheduling exists for this compound.
Designated as a controlled substance as of March 20, 2023. Possession, production, and distribution are prohibited under national drug control legislation.
Placed under legal control in July 2022 on a temporary but renewable basis under the national drug scheduling system.
Considered a controlled substance as a defined derivative of lysergic acid under Verzeichnis E, point 263 of the Swiss narcotics scheduling. Permitted when used exclusively for scientific or industrial purposes.
Illegal to produce, supply, or import under the Psychoactive Substances Act 2016, which came into effect on May 26, 2016. The Act creates a blanket ban on psychoactive substances intended for human consumption. Personal possession is not criminalized under this Act.
7 sources cited
